Adaptimmune Therapeutics PLC Files 8-K
| Field | Detail |
|---|---|
| Company | Adaptimmune Therapeutics PLC |
| Form Type | 8-K |
| Filed Date | Aug 7, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $478,135, $30,965.73, $460,639, $148,830, $1.33579 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting
Related Tickers: ADAP
TL;DR
Adaptimmune filed an 8-K on Aug 7, 2025, covering leadership changes and financials.
AI Summary
Adaptimmune Therapeutics PLC filed an 8-K on August 7, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This filing provides updates on the company's leadership and financial reporting, which are crucial for investors to understand the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate governance and financial statements, with no immediate indication of significant risk.
Key Players & Entities
- Adaptimmune Therapeutics PLC (company) — Registrant
- August 7, 2025 (date) — Date of earliest event reported
FAQ
What specific leadership changes are reported in this 8-K filing?
The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers.
What other information is included in this 8-K filing besides leadership changes?
The filing also includes information on compensatory arrangements of certain officers, as well as financial statements and exhibits.
What is the date of this 8-K filing?
The date of the earliest event reported is August 7, 2025.
What is the primary business of Adaptimmune Therapeutics PLC?
Adaptimmune Therapeutics PLC is in the business of Biological Products (No Diagnostic Substances).
Where is Adaptimmune Therapeutics PLC incorporated?
Adaptimmune Therapeutics PLC is incorporated in England and Wales.
Filing Stats: 1,271 words · 5 min read · ~4 pages · Grade level 11.8 · Accepted 2025-08-07 16:30:12
Key Financial Figures
- $478,135 — base salary for 2025, in the amount of $478,135, less all applicable deductions and wit
- $30,965.73 — ciliation Act of 1985 ( COBRA) totaling $30,965.73. These payments will be made in lump-su
- $460,639 — of 344,844 (equivalent to approximately $460,639*) subject to deduction of applicable ta
- $148,830 — to 111,417 (equivalent to approximately $148,830*) and reimbursement of healthcare benef
- $1.33579 — terling/U.S. dollar exchange rate of (1/$1.33579). Item 9.01 Financial Statements and E
Filing Documents
- adap-20250807x8k.htm (8-K) — 43KB
- adap-20250807xex10d1.htm (EX-10.1) — 41KB
- adap-20250807xex10d2.htm (EX-10.2) — 27KB
- adap-20250807xex10d2001.jpg (GRAPHIC) — 2KB
- adap-20250807xex10d2002.jpg (GRAPHIC) — 9KB
- adap-20250807xex10d2005.jpg (GRAPHIC) — 4KB
- adap-20250807xex10d2006.jpg (GRAPHIC) — 1KB
- 0001558370-25-010785.txt ( ) — 262KB
- adap-20250807.xsd (EX-101.SCH) — 4KB
- adap-20250807_lab.xml (EX-101.LAB) — 16KB
- adap-20250807_pre.xml (EX-101.PRE) — 11KB
- adap-20250807x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 10.1 Separation Agreement dated as of August 7, 2025 by and between Adaptimmune, LLC and Elliot Norry. 10.2 Brewer Letter Agreement dated August 7, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. ADAPTIMMUNE THERAPEUTICS PLC Date: August 7, 2025 By: /s/ Margaret Henry Name: Margaret Henry Title: Corporate Secretary